Corvus Pharmaceuticals, Inc. Initial Public Offering

Davis Polk advised the joint book-running managers and representatives of the several underwriters in the $70.5 million initial public offering by Corvus Pharmaceuticals, Inc. of 4,700,000 shares of its common stock.

The shares are listed on the NASDAQ Global Market under the symbol “CRVS.”

Corvus is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies.

The Davis Polk corporate team included partner Bruce K. Dallas and associates Jeffrey C. Lau, Judy Lai and Ingrid L. Perez. The tax team included partner Rachel D. Kleinberg and associate Alexander Wu. Associate Michelle Gross provided intellectual property and technology advice. Counsel Marcie A. Goldstein provided FINRA advice. Associate Brantley Hawkins provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.